RE:It's the final countdown!
U.S. FDA set to rule on controversial Biogen Alzheimer's drug
June 7 (Reuters) - The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.
Aducanumab has been at the center of a divisive public battle. The Food and Drug Administration is under enormous pressure from patient advocacy groups and some doctors to approve the first major drug for the mind-wasting condition, while many experts say huge amounts of money will be spent despite a lack of compelling evidence aducanumab can provide meaningful benefit.
https://www.google.ca/amp/s/finance.yahoo.com/amphtml/news/u-fda-set-rule-controversial-100000570.html
quote=Gbathat]Tomorrow is a big day for PMN.
If aducanumab is approved, I expect we'll hear about phase 1 funding for PMN310 not too long after.
If it is not approved, I still see potential for PMN310 getting to Phase 1, and we still have the COVID serology testing updates to look forward to...
Glta
[/quote]